

07<sup>th</sup> November, 2025

The Dy. General Manager (Listing Dept.)  
BSE Limited,  
Corporate Relationship Dept.,  
1<sup>st</sup> Floor, New Trading Ring,  
P. J. Towers, Dalal Street, Fort,  
Mumbai - 400 001  
**(BSE Scrip Code: 500420)**

The Manager – Listing Dept.,  
National Stock Exchange of India Ltd.,  
Exchange Plaza, 5<sup>th</sup> Floor,  
Plot No. C/1, G. Block,  
Bandra - Kurla Complex, Bandra (E),  
Mumbai – 400 051  
**(NSE Scrip Code: TORNTPHARM)**

Dear Sir,

**Sub.: Presentation to analysts on unaudited Consolidated Financial Results for the quarter and half year ended 30<sup>th</sup> September, 2025**

The presentation on unaudited Consolidated Financial Results for the quarter and half year ended 30<sup>th</sup> September, 2025 to be made to analysts is enclosed for your records.

Thanking you,

Yours Sincerely,

For TORRENT PHARMACEUTICALS LIMITED

CHINTAN M. TRIVEDI  
COMPANY SECRETARY

Encl: A/a

---

**TORRENT PHARMACEUTICALS LIMITED**

CIN: L24230GJ1972PLC002126

Reg.Office : Torrent House, Off Ashram Road, Ahmedabad- 380 009, India. Phone: +91 79 26599000, Fax: +91 79 26582100,  
www.torrentpharma.com, Email : InvestorServices@TorrentPharma.com



## Q2 FY 2025-26

Revenues: Summary



# Revenue: Summary

Revenues (Rs cr)	Q2 FY26	Q2 FY25	Gr%
India	1820	1632	12%
United States	337	268	26%
Germany	303	288	5%
Brazil	318	263	21%
Others	524	438	20%
Total	3302	2889	14%



# Revenue: Summary

Revenues (Rs cr)	H1 FY26	H1 FY25	Gr%
India	3631	3267	11%
United States	646	527	23%
Germany	612	572	7%
Brazil	536	459	17%
Others	1055	923	14%
Total	6480	5748	13%

